October 16, 2025 — Leads & Copy — Enveric Biosciences (NASDAQ: ENVB) has announced the issuance of its 23rd patent by the USPTO for novel compounds within its neuroplastogenic patent estate. U.S. Patent No. 12,428,408, is titled, “Fused Heterocyclic Mescaline Derivatives,” and covers a series of compounds designed to target serotonin receptors and drive neuroplasticity.
Joseph Tucker, Ph.D., Director and CEO of Enveric, stated that this 23rd patent demonstrates the company’s commitment to developing a strong intellectual property portfolio for potential neuropsychiatric condition treatments.
Enveric Biosciences is focused on developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. Their lead candidate, EB-003, is designed to selectively engage both 5-HT₂A and 5-HT₁B receptors for antidepressant and anxiolytic effects.
For more information, visit www.enveric.com.
Joseph Tucker, Ph.D., Director and CEO of Enveric.
